Literature DB >> 10353638

Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides.

P S Dragovich1, R Zhou, D J Skalitzky, S A Fuhrman, A K Patick, C E Ford, J W Meador, S T Worland.   

Abstract

The optimization of a series of irreversible human rhinovirus (HRV) 3C protease (3CP) inhibitors is described. These inhibitors are comprised of an L-Leu-L-Phe-L-Gln tripeptide containing an N-terminal amide moiety and a C-terminal ethyl propenoate Michael acceptor. Examination of approximately 500 compounds with varying N-terminal amides utilizing solid-phase synthesis and high-throughput assay techniques is described along with the solution phase preparation of several highly active molecules. A tripeptide Michael acceptor containing an N-terminal amide derived from 5-methylisoxazole-3-carboxylic acid is shown to exhibit potent, irreversible anti-3CP activity (k(obs)/[I] = 260,000 M(-1) s(-1); type-14 3CP) and broad-spectrum antirhinoviral properties (average EC50 = 0.47 microM against four different HRV serotypes).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353638     DOI: 10.1016/s0968-0896(99)00005-x

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

1.  Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Authors:  D A Matthews; P S Dragovich; S E Webber; S A Fuhrman; A K Patick; L S Zalman; T F Hendrickson; R A Love; T J Prins; J T Marakovits; R Zhou; J Tikhe; C E Ford; J W Meador; R A Ferre; E L Brown; S L Binford; M A Brothers; D M DeLisle; S T Worland
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor.

Authors:  L S Zalman; M A Brothers; P S Dragovich; R Zhou; T J Prins; S T Worland; A K Patick
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.

Authors:  A K Patick; S L Binford; M A Brothers; R L Jackson; C E Ford; M D Diem; F Maldonado; P S Dragovich; R Zhou; T J Prins; S A Fuhrman; J W Meador; L S Zalman; D A Matthews; S T Worland
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.

Authors:  S L Binford; F Maldonado; M A Brothers; P T Weady; L S Zalman; J W Meador; D A Matthews; A K Patick
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

5.  From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.

Authors:  Matthias Göhl; Linlin Zhang; Haifa El Kilani; Xinyuanyuan Sun; Kaixuan Zhang; Mark Brönstrup; Rolf Hilgenfeld
Journal:  Molecules       Date:  2022-07-04       Impact factor: 4.927

6.  In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.

Authors:  S L Binford; P T Weady; F Maldonado; M A Brothers; D A Matthews; A K Patick
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

7.  Antiviral agents against COVID-19: structure-based design of specific peptidomimetic inhibitors of SARS-CoV-2 main protease.

Authors:  Vladimir Frecer; Stanislav Miertus
Journal:  RSC Adv       Date:  2020-11-04       Impact factor: 4.036

8.  Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.

Authors:  Linlin Zhang; Daizong Lin; Xinyuanyuan Sun; Ute Curth; Christian Drosten; Lucie Sauerhering; Stephan Becker; Katharina Rox; Rolf Hilgenfeld
Journal:  Science       Date:  2020-03-20       Impact factor: 47.728

9.  α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment.

Authors:  Linlin Zhang; Daizong Lin; Yuri Kusov; Yong Nian; Qingjun Ma; Jiang Wang; Albrecht von Brunn; Pieter Leyssen; Kristina Lanko; Johan Neyts; Adriaan de Wilde; Eric J Snijder; Hong Liu; Rolf Hilgenfeld
Journal:  J Med Chem       Date:  2020-02-24       Impact factor: 7.446

Review 10.  COVID-19: inflammatory responses, structure-based drug design and potential therapeutics.

Authors:  Neetu Tripathi; Neeraj Tripathi; Manoj Kumar Goshisht
Journal:  Mol Divers       Date:  2021-01-05       Impact factor: 3.364

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.